Based on the above, we speculate that in the early stage of AD, a small amount of Aβ aggregation may result in a compensatory increase in the expression level of LPL, and thus treated as a molecular chaperone to promote uptake of Aβ for subsequent degradation in the lysosome. Here, LPL is linked to Alzheimer disease.